References
- Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest., in press
- Slovin S. F. Vaccines as treatment strategies for relapsed prostate cancer. Approaches for induction of immunity. Hematol./Oncol. Clin. North Am. 2001; 15: 477–496
- Rosenberg S. A., Yang J. C., Schwarzentruber D. J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998; 4: 321–327
- Small E. J., Fratesi P., Reese D. M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000; 18: 3894–3903
- Dhodapkar M., Steinmann R. M., Sapp M., et al. Rapid generation of broad T-cell immunity in humans after single injection of mature dendritic cells. J. Clin. Invest. 1999; 104: 173–180
- Dhodapkar M., Steinmann R. M., Krasovsky J., et al. Antigen specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 2001; 193: 233–238
- Steinmann R. M., Sdhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 2001; 94: 459–473
- Sloan J. M., Kershaw M. H., Touloukian C. E., et al. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther. 2002; 9: 946–950